AbsorbaSeal 5.6.7F Vascular Closure Device
Cyndrx, LLC · Decision date Jun 5, 2026
What did the FDA approve?
FDA records P230038 as an original PMA application. The recorded decision is approval, dated Jun 5, 2026.
FDA approval order statement
the AbsorbaSeal 5.6.7F Vascular Closure Device. This device is indicated for use in percutaneous closure of femoral arterial access sites while reducing times to hemostasis and ambulation in patients who have undergone diagnostic or interventional catheterization procedures utilizing 5, 6, or 7F procedural sheaths.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Cardiovascular
- Decision date
- Jun 5, 2026
Regulatory record facts
- Identifier
- P230038
- Regulatory pathway
- Premarket approval application
- Applicant
- Cyndrx, LLC
- Product code
- MGB
- Decision code
- APPR
- Decision date
- Jun 5, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Device, hemostasis, vascular.
- Applicant
- Cyndrx, LLC
- Product code
- MGB
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P230038 received
Application receipt date recorded by FDA.
P230038 · FDA decision
APPR
Timeline entries are records held by MedtechLedger for P230038. View FDA’s full supplement list.
Related devices and submissions
Explore the linked device profile
Other records with product code MGB
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Abbott Vascular, Inc. | PMA supplement | Nov 4, 2026 | FDA | |
CELT ACD VASCULAR CLOSURE DEVICEP150006/S009 | Vasorum, Ltd. | PMA supplement | Oct 30, 2026 | FDA |
| Abbott Vascular, Inc. | PMA supplement | Oct 26, 2026 | FDA | |
| Vivasure Medical , Ltd. | PMA approval | Oct 16, 2026 | FDA | |
| Abbott Vascular, Inc. | PMA supplement | Sep 24, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Cyndrx, LLC
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 205 Powell Pl., Suite 124, Brentwood, TN, 37027
Sources and methodology
- Original FDA record: P230038
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


